A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine.
about
Roads to the development of improved pertussis vaccines paved by immunologyReview of the neutrophil response to Bordetella pertussis infection.Vaccine-Mediated Activation of Human TLR4 Is Affected by Modulation of Culture Conditions during Whole-Cell Pertussis Vaccine Preparation.Strategies and new developments to control pertussis, an actual health problemTranscriptome signature for dampened Th2 dominance in acellular pertussis vaccine-induced CD4(+) T cell responses through TLR4 ligation.Bordetella pertussis outer membrane vesicle vaccine confers equal efficacy in mice with milder inflammatory responses compared to a whole-cell vaccine.Emerging Bordetella pertussis Strains Induce Enhanced Signaling of Human Pattern Recognition Receptors TLR2, NOD2 and Secretion of IL-10 by Dendritic Cells.Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.The adjuvant Bordetella Colonization Factor A attenuates alum-induced Th2 responses and enhances Bordetella pertussis clearance from mouse lungs.CD4 T Cells Following Infection and Immunization: Implications for More Effective Vaccine Design
P2860
Q26782939-98454D7E-2B3E-4014-B806-6036A59F9439Q30278579-E34379B5-E234-44F2-9688-EFD6CC1E1CAAQ36109040-9903D671-D1E4-45B6-94F6-77945EACE0ACQ36226470-519C54C1-B138-4945-9ACE-D77CA6E7DDF9Q36841068-7D4156DB-2914-469D-B54B-91A9E8053B65Q37460023-2DF4769D-B73D-4CEE-B6AE-46C5CB7283E1Q37580659-91315B0D-AE9A-46A6-8A65-6A73F45AFDA2Q38685505-DB0DF9CB-3D63-484C-B9F4-C11C811F0DADQ40295958-40F4E950-F8F6-496F-8CA6-17F38A916406Q49822345-EA099D2D-67FE-4AAD-B21E-92434BD5B504Q51741065-D2FF3F51-EED8-47EB-A49B-41D8888EF55DQ58790016-E3A98FF8-8CBA-4ED2-8C2B-C2173BE6871F
P2860
A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A novel TLR2 agonist from Bord ...... n acellular pertussis vaccine.
@en
type
label
A novel TLR2 agonist from Bord ...... n acellular pertussis vaccine.
@en
prefLabel
A novel TLR2 agonist from Bord ...... n acellular pertussis vaccine.
@en
P2093
P2860
P50
P356
P1433
P1476
A novel TLR2 agonist from Bord ...... an acellular pertussis vaccine
@en
P2093
C C Cunningham
C E Sutton
S C Higgins
P2860
P2888
P304
P356
10.1038/MI.2014.93
P577
2014-10-15T00:00:00Z